---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-25-000151"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:30:44.654609+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q2 revenue up 10% to $181M but net loss widens to $45M; cuts full-year guidance

## Summary
- Revenue $181M (+10% YoY); clinical revenue grew 16% (13% ex-Pathline).
- Net loss widened 142% to $45M including $20M impairment charges.
- Adjusted EBITDA flat at $10.7M vs $10.9M last year.
- Full-year 2025 revenue guidance cut to $720-$726M (prev $747-$759M); Adj EBITDA guidance lowered to $41-$44M.
- Acquired Pathline for $8M cash plus $1M contingent consideration in April 2025.

## SEC filing metadata
- accession: 0001077183-25-000151
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000151/0001077183-25-000151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000151/neo-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-25-000151
- JSON: https://secwatch.observer/filing/0001077183-25-000151.json
- Plain text: https://secwatch.observer/filing/0001077183-25-000151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.